Bose Subhasish, Kanda Brinder, Roy Sasmit, Saum Kenneth, Haas John, El-Adhab Fadi, Ranson Crystal, Brunton Nichole, Morford Reagan, Tavaf-Motamen Houman
Internal Medicine, Liberty University College of Osteopathic Medicine, Lynchburg, USA.
Nephrology, University of Virginia, Lynchburg, USA.
Cureus. 2022 Dec 23;14(12):e32878. doi: 10.7759/cureus.32878. eCollection 2022 Dec.
Transcatheter aortic valve replacement (TAVR) is now regarded as a viable treatment option for all cases of severe aortic stenosis (AS). Acute kidney injury (AKI) is common and lowers the survival of patients after TAVR and iodine-based contrast-induced nephropathy (CIN) plays a significant adverse role in AKI. Therefore, in chronic kidney disease (CKD) patients requiring pre-operative evaluation for TAVR, the risk of CIN is of particular concern.
It was a single-center study including eight CKD patients who underwent pre-operative evaluation for TAVR with minimized contrast exposure by means of pre-operative contrast-sparing evaluation and intra-operative contrast minimization. All patients had glomerular filtration rate (eGFR) calculated before TAVR and on a follow-up about one month and one year post-operatively to document the impact of this TAVR protocol on prognosis of kidney function in patients with advanced CKD.
New York Heart Association (NYHA) functional classification demonstrated significant improvement of symptomatology (p = 0.0001) by one-year post-TAVR. Patients' mean AS gradient was significantly improved (p = 0.00004) after the TAVR procedure. No significant post-operative paravalvular aortic regurgitation was noted on follow up echocardiogram. eGFR data showed mean eGFR for the group was slightly better (27.38 ml/min/per 1.73 m BSA vs. 30.38 ml/min/per 1.73 m BSA) after TAVR.
"Contrast frugal" approach is feasible and safe for pre-TAVR evaluation and the procedure itself. Our pilot study showed no significant paravalvular leak of the prosthetic valve following this proposed protocol. No statistically significant decrease in eGFR was noted on a one-year follow-up.
经导管主动脉瓣置换术(TAVR)目前被视为所有严重主动脉瓣狭窄(AS)病例的可行治疗选择。急性肾损伤(AKI)很常见,会降低TAVR术后患者的生存率,而碘造影剂诱发的肾病(CIN)在AKI中起重要的不良作用。因此,在需要进行TAVR术前评估的慢性肾脏病(CKD)患者中,CIN的风险尤其值得关注。
这是一项单中心研究,纳入了8例接受TAVR术前评估的CKD患者,通过术前造影剂节省评估和术中造影剂最小化,使造影剂暴露降至最低。所有患者在TAVR术前以及术后约1个月和1年的随访中计算肾小球滤过率(eGFR),以记录该TAVR方案对晚期CKD患者肾功能预后的影响。
纽约心脏协会(NYHA)功能分级显示,TAVR术后1年症状有显著改善(p = 0.0001)。TAVR术后患者的平均AS压差显著改善(p = 0.00004)。随访超声心动图未发现明显的术后人工瓣膜瓣周主动脉反流。eGFR数据显示,TAVR术后该组的平均eGFR略有改善(27.38 ml/min/每1.73 m²体表面积 vs. 30.38 ml/min/每1.73 m²体表面积)。
“节省造影剂”方法对于TAVR术前评估及其手术本身是可行且安全的。我们的初步研究表明,按照此方案进行手术后,人工瓣膜没有明显的瓣周漏。1年随访中未发现eGFR有统计学意义的下降。